Research map: Real-world effectiveness of fostamatinib in patients with immune thrombocytopenia: a single-center retrospective study

Back to the article

Papers in this map

  1. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group · Francesco Rodeghiero · 2008 · 2708 citations · Cited by this paper
  2. Recent advances in the pathophysiology and treatment of GVHD · 2026 · Related
  3. Updated international consensus report on the investigation and management of primary immune thrombocytopenia · Drew Provan · 2019 · 1151 citations · Cited by this paper
  4. Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria · 2026 · Related
  5. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials · James Bruce Bussel · 2018 · 368 citations · Cited by this paper
  6. Current status and challenges of TCR-T cell therapy for AML/MDS · 2026 · Related
  7. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia · Ken Kaito · 2005 · 299 citations · Cited by this paper
  8. T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel · 2026 · Related
  9. Splenic macrophages maintain the anti‐platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura · Masataka Kuwana · 2008 · 146 citations · Cited by this paper
  10. NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives · 2026 · Related
  11. Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program · James Bruce Bussel · 2019 · 121 citations · Cited by this paper
  12. Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan · 2026 · Related
  13. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial · Catherine M. Broome · 2023 · 103 citations · Cited by this paper
  14. Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms · 2026 · Related
  15. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib · Nichola Cooper · 2022 · 87 citations · Cited by this paper
  16. Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study · 2026 · Related
  17. Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia · Ralph Vincent Boccia · 2020 · 72 citations · Cited by this paper
  18. Zanubrutinib for MYD88-negative Waldenström’s macroglobulinemia with massive splenomegaly · 2026 · Related
  19. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision · Hirokazu Kashiwagi · 2020 · 66 citations · Cited by this paper
  20. Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan · 2026 · Related
  21. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib · Nichola Cooper · 2021 · 64 citations · Cited by this paper
  22. Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study · David J. Kuter · 2025 · 50 citations · Cited by this paper
  23. Fostamatinib: A Review in Chronic Immune Thrombocytopenia · Julia Paik · 2021 · 38 citations · Cited by this paper
  24. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI) · María Eva Mingot‐Castellano · 2023 · 36 citations · Cited by this paper
  25. Mean Platelet Volume, Platelet Distribution Width, and Platelet Count, in Connection with Immune Thrombocytopenic Purpura and Essential Thrombocytopenia · Eun‐Yup Lee · 2018 · 29 citations · Cited by this paper
  26. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo‐controlled, double‐blind, parallel‐group study · Masataka Kuwana · 2022 · 29 citations · Cited by this paper
  27. Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study · Luca Frison · 2018 · 18 citations · Cited by this paper
  28. Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia · María Eva Mingot‐Castellano · 2024 · 14 citations · Cited by this paper
  29. Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study · Masataka Kuwana · 2024 · 9 citations · Cited by this paper
  30. Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia · Masataka Kuwana · 2025 · 6 citations · Cited by this paper
  31. Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience · Donald C. Moore · 2024 · 4 citations · Cited by this paper
  32. A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia · Hiroki Yamaguchi · 2025 · 4 citations · Cited by this paper
  33. Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan · Hirokazu Kashiwagi · 2024 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)